Spyre Therapeutics Inc (SYRE)

$SYRE just reverted 5% higher to -13% (~514Kv) a few minutes ago, 06/20 options, follow for more volatility.

$SYRE they obviously have a lot of immunogenicity in their phase 1 study which is why they’re not disclosing the incidence, and so the HUGE question is what happens when they give a second dose? Of course there is no impact of immunogenicity when a single dose is given to treatment naive subjects, but dosing subjects with pre-existing ADA (from the first dose) could be a very different situation.

$SYRE Spyre Therapeutics reports positive interim Phase 1 results for TL1A antibodies Spyre Therapeutics announced positive interim Phase 1 results from its first-in-human trials of SPY002 and SPY072, two investigational, novel, extended half-life monoclonal antibodies targeting TL1A. In addition, the company is initiating its SKYLINE-UC platform trial and unveiled its SKYWAY-RD basket trial evaluating anti-TL1A targeted therapy in three rheumatologic indications. Interim results from the Phase 1 trials for SPY002 and SPY072, with data reported as of May 30, 2025, met all Phase 1 objectives, supporting their potential to become next-generation anti-TL1A monotherapies in immune-mediated diseases or as elements of combination therapies. Single doses of up to 1500 mg for SPY002 and SPY072 were well tolerated with no serious adverse events reported, exhibited a prolonged half-life supportive of quarterly or less frequent dosing, and suppressed free TL1A through 20 weeks of follow up available for the lowest dose tested. Building on these Phase 1 results, Spyre is advancing SPY002 into the SKYLINE-UC platform trial - initiated in May 2025 - for ulcerative colitis. SKYLINE-UC is expected to include SPY001, SPY002, SPY003, and combinations thereof under an efficient single master protocol. The SKYWAY-RD study is a Phase 2 basket trial investigating Spyre's improved anti-TL1A as a treatment for RA, PsA, and axSpA and is expected to initiate in Q3 2025. In 2026 the company expects to readout open-label monotherapy data for its three investigational long-acting antibodies from the SKYLINE-UC trial along with three placebo-controlled readouts for SPY072 in RA, PsA, and axSpA from the SKYWAY-RD trial. In 2027, the company expects to read out placebo-controlled data of its monotherapies and combination therapies from the SKYLINE-UC study.

$SYRE Spyre Therapeutics Announces Interim Phase 1 Results For Two Next-Generation TL1A Antibody Programs, And Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

$SYRE Spyre Therapeutics, watch for a narrow range breakout at https://stockconsultant.com/?SYRE

$SYRE Spyre Therapeutics stock, watch for a bottom breakout above 15.47 at https://stockconsultant.com/?SYRE

$SYRE CYDY

$SYRE 100,6% Institutional ownership, EV 280m. Okay.

$SYRE Only candidate right now for the SWTX gains. Will do some DD later this week.

$ARWR $VRDN $ORKA $SYRE so far so good